Compare ADXN & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADXN | SONM |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.7M |
| IPO Year | 2019 | 2019 |
| Metric | ADXN | SONM |
|---|---|---|
| Price | $3.40 | $1.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 773.2K | 11.9K |
| Earning Date | 11-23-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.89 |
| Revenue | N/A | ★ $58,298,000.00 |
| Revenue This Year | $767.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.54 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.56 | $2.02 |
| 52 Week High | $10.43 | $8.15 |
| Indicator | ADXN | SONM |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 26.60 |
| Support Level | $2.77 | N/A |
| Resistance Level | $3.52 | $4.40 |
| Average True Range (ATR) | 0.46 | 0.33 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 19.11 | 13.48 |
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
DNA X Inc is engaged in providing crypto trading services through its online platform, enabling users to buy, sell, and exchange cryptocurrencies, as well as execute automated trading strategies between currency pairs. The company generates revenue from commissions and fees on trading activity.